Non-linear fluvoxamine disposition

British Journal of Clinical Pharmacology

Volumn 45, Issue 3, 1998, Pages 257-263

  Spigset, Olav ^a,b   Granberg, Kerstin ^a   Hägg, Staffan ^a   Söderström, Emma ^a   Dahlqvist, Rune ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adverse drug reactions; CYP1A2; CYP2D6; Disposition; Fluvoxamine; Non linear; Pharmacokinetics

Indexed keywords

CAFFEINE; DEXTROMETHORPHAN; FLUVOXAMINE; FLUVOXAMINE MALEATE; MEPHENYTOIN; TUSSIDYL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG SALIVA LEVEL; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MAINTENANCE THERAPY; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; TECHNIQUE;

ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP2D6; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUVOXAMINE; HUMANS; MALE; SEROTONIN UPTAKE INHIBITORS;

EID: 0031915975     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00670.x     Document Type: Article

References (29)

1. Wilde MI, Plosker GL, Benfield P. Fluvoxamine. Drugs 1993; 46: 895-924.
2. Palmer KH, Benfield P. Fluvoxamine. CNS Drugs 1994; 1: 57-87.
3. de Bree H, van der Schoot JB, Post LC. Fluvoxamine maleate: disposition in man. Eur J Drug Metabolism Pharmacokinet 1983; 8: 175-179.
4. van Harten J, Lönnebo A, Grahnén A. Pharmacokinetics of fluvoxamine after intravenous and oral administration [abstract]. Neuropsychopharmacology 1994; 10: 104S.
5. Spigset O, Carleborg L, Hedenmalm K, Dahlqvist R. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58: 399-403.
6. Spigset O, Granberg K, Hägg S, Norström Å, Dahlqvist R. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 polymorphisms. Eur J Clin Pharmacol 1997; 52: 129-133.
7. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993; 45: 1211-1214.
8. Skjelbo E, Brosen K. Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 1992; 34: 256-261.
9. Spina E, Pollicino AM, Avenoso A, Campo GM, Perucca E, Caputi AP. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. Ther Drug Monit 1993; 15: 243-246.
10. Sperber AD. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy. Drug Saf 1991; 6: 460-462.
11. Donaldsson KM, Wright DM, Mathlener IS, Harry JD. The effect of fluvoxamine at steady state on the pharmacokinetics of theophylline after a single dose in healthy male volunteers. Br J Clin Pharmacol 1994; 37: 492P.
12. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-78.
13. Jeppesen U, Loft S, Poulsen HE, Brosen K. A fluvoxamine-caffeine interaction study. Pharmacogenesis 1996; 6: 213-222.
14. Dahlqvist R, Billing B, Miners JO, Birkett DJ. Nonlinear metabolic disposition of theophylline. Ther Drug Monit 1984; 6: 290-297.
15. Kamimori GH, Lugo SI, Penetar DM, et al. Dose-dependent caffeine pharmacokinetics during severe sleep deprivation in humans. Int J Clin Pharmacol Ther 1995; 33: 182-186.
16. Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, theophylline and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987; 15: 237-248.
17. Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-295.
18. de Vries MH, Raghoebar M, Mathlener IS, van Harten J. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14: 493-598.
19. Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-witching high-performance liquid chromatography. Clin Chem 1992; 38: 2082-2086.
20. de Vries MH, van Harten J, van Bemmel P, Raghoebar M. Pharmacokinetics of fluvoxamine maleate after single oral doses in healthy subjects. Biopharm Drug Dispos 1993; 14: 291-296.
21. Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175-190.
22. Spigset O, Öhman R. Case of fluvoxamine intoxication demonstrating non-linear elimination pharmacokinetics. J Clin Psychopharmacol 1996; 16: 255-256.
23. van Harten J, Duchier J, Devissaguet J-P, van Bemmel P, de Vries MH, Raghoebar M. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis aticr single-dose oral administraton. Clin Pharmacokinet 1993; 24: 177-182.
24. Sanz EJ, Villén T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989; 45: 495-499.
25. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4: 109-116.
26. Carrillo JA, Dahl M-L, Svensson J-O, Alm C, Rodríguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996; 60: 183-190.
27. Kasper S, Dötsch M, Kick H, Vieira A, Möiler H-J. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13-21.
28. Klok CJ, Brouwer GJ, van Praag HM, Doogan D. Fluvoxamine and clomipramine in depressed patients. Acta Psychiatr Scand 1981; 64: 1-11.
29. de Wilde JEM, Doogan DP. Fluvoxamine and chlorimipramine in endogenous depression. J Affect Disord 1982; 4: 249-259.